Table 2 Univariate and multivariate logistic regression analysis for predicting clinical benefit group with PD-1 blockade

From: Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients

Variables

Univariate

Multivariate

Odds ratio (95% CI)

p value

B

β

t

p value

CD3+ TIL

1.002 (1.000–1.003)

0.017

0.001

0.622

1.652

0.014

CD8+ TIL

1.004 (1.000–1.007)

0.037

NS

   

CD8+/CD3+ TIL ratio

1.034 (0.996–1.074)

0.301

    

FOXP3+/CD8+ TIL ratio

0.941 (0.897–0.986)

0.027

−0.005

−0.344

−2.265

0.03

PD-1+/CD8+ TIL ratio

0.969 (0.9539–1.001)

0.087

    

PD-L1 protein expression

Positive (≥1%)

4.421 (0.477–40.980)

0.207

    

Strong positive

1.125 (0.292–4.335)

0.806

    

TIIC≥ 50%

1.236 (0.989–1.545)

0.063

    

Age ≥ 65 years

0.281 (0.073–1.084)

0.065

    

Ever/current smoker

0.778 (0.195–3.103)

0.722

    

Presence of driver mutation

0.274 (0.050–1.494)

0.135

    

Type of PD-1 blockade

2.133 (0.505–9.010)

0.303

    
  1. TIL tumor infiltrating lymphocyte, CD cluster of differentiation, FOXP3 forkhead box P3, PD-1 programmed cell death protein-1, PD-L1 programmed-cell death ligand-1, TIIC tumor infiltrating inflammatory cells, CI confidence interval, NA not significant
Back to article page